Eli Lilly

Founded 1876
Founders Eli Lilly


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 39
Average round size
The average size of a deal this fund participated in
Portfolio companies 37
Rounds per year 0.27
Lead investments 11
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 17
Key employees 4

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics

Eli Lilly appeared to be the Corporate Investor, which was created in 1876. The main office of represented Corporate Investor is situated in the Indianapolis. The fund was located in North America if to be more exact in United States.

The common things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Eli Lilly performs on 0 percentage points less the average number of lead investments. The high activity for fund was in 2016. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies.

Besides them, we counted 4 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Eli Lilly, startups are often financed by Skyline Ventures, SV Health Investors, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Innovation, ARCH Venture Partners, Watson Fund. In the next rounds fund is usually obtained by RTW Investments LLC, Zesiger Capital, Unilever Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Immunocore, Perlegen Sciences, ImmunoGen. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Biotechnology, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Iterative Scopes

Computer Vision
Health Care
Health Diagnostics
$30M03 Aug 2021 Cambridge, Massachusetts, United States

MiNA Therapeutics

Drug Discovery
$15M06 Jul 2021 London, England, United Kingdom

TRex Bio

$59M22 Jun 2021 South San Francisco, California, United States

DTx Pharma

$100M01 Mar 2021 San Diego, California, United States

Evox Therapeutics

Health Care
$94M18 Feb 2021 Oxford, England, United Kingdom

Auron Therapeutics

Health Care
$12M28 Jan 2021 Massachusetts, United States

Blacksmith Medicines

Life Science
08 Jan 2021 San Diego, California, United States

Terns Pharmaceuticals

Health Care
Medical Device
$87M05 Jan 2021 California, United States

Faze Medicines

$81M10 Dec 2020 Cambridge, Massachusetts, United States
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Eli Lilly?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: